Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266884 | 0.84 | HSD17B10 (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL8258234 | 0.84 | HSD17B10 (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2266882 | 0.84 | HSD17B10 (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL8138198 | 0.83 | ANPEP (0.55) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL11926262 | 0.83 | NOS1 (0.48) | TSHRALDH1A1SMN1; SMN2TDP1POLB | |
| SCHEMBL4878931 | 0.80 | ANPEP (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2129856 | 0.80 | ANPEP (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| Terephthalic Acid SCHEMBL8743590 | 0.80 | ANPEP (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL4448319 | 0.80 | ANPEP (0.57) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL1753887 | 0.80 | TSHR (0.55) | ANPEPTSHRTP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103172528-B | Tranexamic acid preparation method | :YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) | 2014-10-08 | — | — | CN | claimed |
| CN-103172528-A | Tranexamic acid preparation method | VALIANT FINE CHEMICALS CO LTD | 2013-06-26 | — | — | CN | claimed |
| CN-110156620-A | A kind of preparation method of tranexamic acid | 中节能万润股份有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-108752226-A | The preparation method of tranexamic acid | 常州兰陵制药有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-102971291-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2015-07-22 | — | — | CN | disclosed |
| CN-103172528-B | Tranexamic acid preparation method | :YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) | 2014-10-08 | — | — | CN | disclosed |
| CN-103172528-B | Tranexamic acid preparation method | :YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) | 2014-10-08 | — | — | CN | disclosed |
| US-8816079-B2 | Amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-103172528-A | Tranexamic acid preparation method | VALIANT FINE CHEMICALS CO LTD | 2013-06-26 | — | — | CN | disclosed |
| CN-103172528-A | Tranexamic acid preparation method | VALIANT FINE CHEMICALS CO LTD | 2013-06-26 | — | — | CN | disclosed |
| CN-102971291-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2013-03-13 | — | — | CN | disclosed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ANPEP 213/4885TSHR 3179/4885TP53 1598/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ANPEP 213/4885TSHR 3179/4885TP53 1598/4885 |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ANPEP 225/4885TSHR 3208/4885TP53 1746/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | ANPEP 213/4885TSHR 3179/4885TP53 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.